West Pharmaceutical Services stock holds near fair value as valuation debate intensifies

West Pharmaceutical Services stock (ISIN US9553061055) is trading around USD 362.31 as of mid September 2026, reflecting a year to date share price return of 31.08 percent and a total shareholder return of 42.61 percent over the past year, according to Simply Wall St on September 20, 2026.

Valuation narratives around WST stock

At a last close of USD 362.31, one widely cited valuation narrative pegs West Pharmaceutical Services at a fair value of about USD 404, implying that the shares could be roughly 10 percent undervalued at current levels, as Simply Wall St reported on September 20, 2026.

Another quantitative model comes to a slightly different conclusion, rating West Pharmaceutical Services as fairly valued with a model fair value of USD 331.50 against the same last close of USD 362.31, which corresponds to a valuation gap of minus 8.5 percent, according to Faircurve on September 19, 2026.

Both views anchor their assessment in a current market value of around USD 25.5 billion for West Pharmaceutical Services and highlight that the stock trades on a price to earnings multiple of about 45.1 times versus approximately 37.8 times for the broader global life sciences industry and 34.3 times for selected peers, with a fair P/E ratio estimated at 23.6 times in the valuation model, as outlined by Simply Wall St on September 20, 2026.

Recent performance and fundamentals context

The strong share price performance, with a 31.08 percent year to date return and a 42.61 percent total shareholder return over the past twelve months, stands in contrast to mildly negative three year and five year total shareholder returns for West Pharmaceutical Services, illustrating how the recent period has been significantly more favorable for shareholders than the longer term, according to the analysis by Simply Wall St dated September 20, 2026.

On the earnings side, the same valuation framework uses a reported net income figure of USD 564.9 million for West Pharmaceutical Services as one of the inputs into the discounted cash flow based fair value estimate of USD 404, as described by Simply Wall St on September 20, 2026.

The discounted cash flow model applies a discount rate of 7.83 percent to derive the fair value of USD 404 per share, illustrating how assumptions about the cost of capital influence whether the current price of USD 362.31 appears attractive or expensive for long term investors, as the methodology from Simply Wall St on September 20, 2026 makes clear.

Key risk factors and sector positioning

The valuation discussion does not ignore risk factors: execution risk around exiting continuous glucose monitoring contracts and exposure to higher tariffs are cited as elements that could unsettle the West Pharmaceutical Services investment case if margins were to falter, according to Simply Wall St on September 20, 2026.

Additional commentary from the medical sector notes that West Pharmaceutical Services benefits from exposure to biologics, Annex 1 related projects and delivery device growth, even as near term headwinds remain in the business, according to Zacks on September 20, 2026.

For investors, this combination of supportive structural trends in biologics and delivery devices, together with specific operational risks around contract exits and tariffs, means that the relatively high earnings multiple of about 45.1 times and the competing fair value estimates of USD 404 and USD 331.50 should be weighed carefully when assessing whether the current share price of USD 362.31 offers attractive risk adjusted return potential, as implied by the analyses on Simply Wall St and Faircurve in mid September 2026.

West Pharmaceutical Services stock price and market data

In New York trading on its primary listing on the New York Stock Exchange, West Pharmaceutical Services stock most recently closed at USD 362.31, with a corresponding market capitalization of about USD 25.5 billion as of mid September 2026; this price level stands below the USD 404 discounted cash flow based fair value cited in one analysis and above the USD 331.50 fair value from another model, illustrating how the shares sit between these two valuation anchors at present.

More news and analyses on West Pharmaceutical Services stock